307 related articles for article (PubMed ID: 6937239)
41. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in neoplastic and normal cells.
Lauzon GJ; Paterson AR; Belch AW
Cancer Res; 1978 Jun; 38(6):1730-3. PubMed ID: 274175
[TBL] [Abstract][Full Text] [Related]
42. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
43. Deoxyguanosine enhancement of cytarabine nucleotide accumulation in human leukemia cells.
Akman SA; Ross DD; Joneckis CC; Fox BM; Bachur NR
Cancer Treat Rep; 1985; 69(7-8):851-7. PubMed ID: 4016794
[TBL] [Abstract][Full Text] [Related]
44. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
Lauzon GJ; Paran JH; Paterson AR
Cancer Res; 1978 Jun; 38(6):1723-9. PubMed ID: 274174
[TBL] [Abstract][Full Text] [Related]
45. 1-beta-D-arabinofuranosylcytosine (ara-C) deamination in human leukemic myeloblasts is not a mechanism of resistance to ara-C therapy.
Harris AL
Cancer Res; 1981 Jul; 41(7):2977-9. PubMed ID: 6941850
[No Abstract] [Full Text] [Related]
46. Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells.
Cadman E; Eiferman F
J Clin Invest; 1979 Sep; 64(3):788-97. PubMed ID: 288743
[TBL] [Abstract][Full Text] [Related]
47. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
Estey EH; Keating MJ; McCredie KB; Freireich EJ; Plunkett W
Leukemia; 1990 Feb; 4(2):95-9. PubMed ID: 2304361
[TBL] [Abstract][Full Text] [Related]
48. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells.
Gandhi V; Plunkett W
Cancer Chemother Pharmacol; 1992; 31(1):11-7. PubMed ID: 1458554
[TBL] [Abstract][Full Text] [Related]
49. Efficient formation of cytosine arabinoside-5'-triphosphate in leukemic blasts of human T-cell acute lymphoblastic leukemia.
Tanaka M; Yoshida S
Leuk Res; 1989; 13(10):931-6. PubMed ID: 2586146
[TBL] [Abstract][Full Text] [Related]
50. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Crews KR; Gandhi V; Srivastava DK; Razzouk BI; Tong X; Behm FG; Plunkett W; Raimondi SC; Pui CH; Rubnitz JE; Stewart CF; Ribeiro RC
J Clin Oncol; 2002 Oct; 20(20):4217-24. PubMed ID: 12377965
[TBL] [Abstract][Full Text] [Related]
51. Concordant changes of pyrimidine metabolism in blasts of two cases of acute myeloid leukemia after repeated treatment with ara-C in vivo.
Chiba P; Tihan T; Szekeres T; Salamon J; Kraupp M; Eher R; Köller U; Knapp W
Leukemia; 1990 Nov; 4(11):761-5. PubMed ID: 2232889
[TBL] [Abstract][Full Text] [Related]
52. 1-beta-D-arabinofuranosylcytosine nucleotide inhibition of sialic acid metabolism in WI-38 cells.
Myers-Robfogel MW; Spataro AC
Cancer Res; 1980 Jun; 40(6):1940-3. PubMed ID: 7371029
[TBL] [Abstract][Full Text] [Related]
53. Relationship between plasma Ara-C and intracellular Ara-CTP pools under conditions of continuous infusion and high-dose Ara-C treatment.
Rustum YM; Slocum HK; Wang G; Bakshi D; Kelly E; Buscaglia D; Wrzosek C; Early AP; Preisler H
Med Pediatr Oncol; 1982; 10 Suppl 1():33-43. PubMed ID: 7162465
[TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetics of N4-behenoyl-1-beta-D-arabinofuranosylcytosine in patients with acute leukemia.
Ueda T; Nakamura T; Ando S; Kagawa D; Sasada M; Uchino H; Johno I; Akiyama Y
Cancer Res; 1983 Jul; 43(7):3412-6. PubMed ID: 6850647
[TBL] [Abstract][Full Text] [Related]
55. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
Chou TC; Hutchinson DJ; Schmid FA; Philips FS
Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
[TBL] [Abstract][Full Text] [Related]
56. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
57. Correlation of drug-perturbed marrow cell growth kinetics and intracellular 1-B-D-arabinofuranosylcytosine metabolism with clinical response in adult acute myelogenous leukemia.
Karp JE; Donehower RC; Dole GB; Burke PJ
Blood; 1987 Apr; 69(4):1134-40. PubMed ID: 3470054
[TBL] [Abstract][Full Text] [Related]
58. Pharmacologically directed design of leukemia therapy.
Plunkett W; Heinemann V; Estey E; Keating M
Haematol Blood Transfus; 1990; 33():610-3. PubMed ID: 2182451
[TBL] [Abstract][Full Text] [Related]
59. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
[TBL] [Abstract][Full Text] [Related]
60. Pharmacology and toxicology of a seven-day infusion of 1-beta-D-arabinofuranosylcytosine plus uridine in dogs.
Perlow L; Ohnuma T; Andrejczuk A; Shafir M; Strauchen J; Holland JF
Cancer Res; 1985 Jun; 45(6):2572-7. PubMed ID: 3986795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]